A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Trial Details

NCT ID

NCT06615479

Phase

PHASE3

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• BMS-986393
• Cyclophosphamide
• Fludarabine
• Daratumumab
• Pomalidomide
• Dexamethasone

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Los Angeles, California, United States|34.05223,-118.24368
• Washington D.C., District of Columbia, United States|38.89511,-77.03637
• Jacksonville, Florida, United States|30.33218,-81.65565
• Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

• Participants must have relapsed or refractory multiple myeloma (RRMM).
• Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI)…
• Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
• Participants must have measurable disease during screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.